Rustin et al., one of the largest prospective cohort studies conducted on the role of CA-125 elevation in the detection of recurrent ovarian cancer, found that the difference between CA-125 elevation and clinical confirmation of recurrence was 4.8 months [11]. Here, MUC16 is linked to ovarian carcinoma.